for the REVEAL-HCV Study Group
C hronic kidney disease (CKD) and resultant end-stage renal disease (ESRD) represent a global health challenge that is associated with high medical costs and poor treatment outcomes. (1) Conventional risk factors for CKD include age, male gender, a history of smoking, diabetes, and hypertension; however, these risk factors cannot fully explain the occurrence of the disease, and new risk factors and markers have been identified. (2) The role of chronic infectious disease, which is a new risk factor, may be underestimated. Previous research has documented an association between hepatitis C virus (HCV) infection and glomerulonephritis. (3) However, our understanding of the relationship between HCV infection and ESRD remains limited.
More than 110 million people worldwide have chronic HCV infection, and around 80 million people are HCV viremic. (4) Chronic liver disease is common in patients with HCV, but 40%-74% of patients develop at least one extrahepatic manifestation. (5) Abbreviations: CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard ratio; ICD-9-CM, International Classification of Disease, 9th edition, Clinical Modification; NHIRD, National Health Insurance Research Database; REVEAL-HCV, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis C Virus.
HCV is associated with various glomerular diseases, particularly membranous proliferative glomerulonephritis in the context of cryoglobulinemia. The majority of cryoglobulinemic HCV-infected patients have either no or negligible clinical manifestations. (6) In observational studies, the prevalence of HCV infection is much higher in patients undergoing dialysis or in those who are new to dialysis than in normal volunteers. (7, 8) Cross-sectional and retrospective studies have explored the relationship between HCV infection, proteinuria, and low glomerular filtration rate (GFR), but the results have been conflicting. (9) (10) (11) (12) (13) (14) (15) In 2007, a US veterans retrospective study demonstrated that HCV seropositivity was associated with a greater than 2-fold risk of developing ESRD; however, the HCV diagnosis was based on a positive HCV antibody test, as in most previous studies. The impacts of the HCV viral load, which represents the degree of active infection, and that of HCV genotypes, which influences the response to antiviral therapy, on the risk of ESRD remain to be clarified.
Taiwan is known to be an HCV-endemic area and shares one of the highest prevalence rates of ESRD worldwide. (16) Unlike HCV-infected patients in other countries who are at risk of drug injections, human immunodeficiency virus (HIV) coinfection, or HCVcontaminated vaccinations, (17, 18) the major risk factors of HCV infection in Taiwan are iatrogenic. (19) The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer (REVEAL)-HCV study, a large prospective community-based cohort study in Taiwan, provides an excellent opportunity to investigate the natural history of chronic hepatitis C and long-term diseases associated with it. (20) This study aimed to assess the risk of developing ESRD in relation to HCV serostatus, HCV RNA level, and HCV genotypes. Accordingly, we conducted a largescale community-based cohort study to determine whether chronic HCV infection is an independent risk factor for ESRD.
Materials and Methods

STUDY COHORT ENROLLMENT
Enrollment and follow-up methods for participants in this community-based prospective study have been described. (21) From 1991 to 1992, a total of 23,820 adults aged 30-65 years living in seven townships in Taiwan agreed to participate in the REVEAL-HCV study and underwent a health examination that included blood collection. All participants were interviewed in person by trained public health nurses using a structured questionnaire. Information was collected on sociodemographic characteristics, smoking history, alcohol consumption, and presence of chronic diseases such as diabetes mellitus, hypertension, and cardiovascular disease. A 10-mL fasting blood sample was obtained from each participant, and samples were fractionated and stored at 2708C until use. All participants were regularly followed up until December 31, 2008 .
After the exclusion of 35 samples not available for anti-HCV testing and 38 subjects with liver cirrhosis,
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there were 23,747 participants recruited who provided informed consent (Fig. 1) . We further excluded 3,572 subjects without baseline serum creatinine data; 61 subjects with stage 5 CKD, defined by a baseline estimated GFR of <15 mL/min; and 130 anti-HCVseropositive subjects without available HCV viral load data, yielding a total of 19,984 participants for the longitudinal analysis. This study was approved by the institutional review board of the College of Public Health, National Taiwan University in Taipei.
ASCERTAINMENT OF EXPOSURE
Serum samples were tested for hepatitis C antibody by enzyme immunoassay using a second-generation commercial kit (Abbott HCV EIA, version 2.0; Abbott Laboratories, North Chicago, IL). Samples positive for anti-HCV were further tested for HCV RNA using the COBAS TaqMan HCV test, version 2.0 (Roche Diagnostics Corporation, Indianapolis, IN). The detection limit for the COBAS TaqMan HCV test was 25 IU/mL. We defined chronic HCVinfected subjects as those with a detectable serum HCV RNA level. We further categorized HCV RNA levels into low and high HCV viral load groups. Because the median detectable HCV RNA level (24,400 IU/mL) at study entry was low, the third quartile of the detectable serum HCV RNA levels was used as a cutoff value (167,000 IU/mL). Detectable HCV RNA was further examined for HCV genotypes using the LightCycler system (Roche Diagnostics Corporation) for PCR and melting curve analysis. HCV genotype was categorized as genotype 1 or genotype 2.
ASCERTAINMENT OF OUTCOME
We linked the REVEAL-HCV cohort to Taiwan's National Health Insurance Research Database (NHIRD). The National Health Insurance is a mandatory program established in 1996 that covers 99% of Taiwan's entire population of 23 million people. The NHIRD provides encrypted patient identification numbers; age; sex; dates of hospital admission and discharge; medical institutions providing services; the International Classification of Disease, 9th edition, Clinical Modification (ICD-9-CM) codes of diagnoses 
ASCERTAINMENT OF COVARIATES
Information collected from the questionnaire included age, sex, smoking (yes/no), alcohol use (yes/ no), education status (literate/illiterate), and history of comorbidities. Laboratory examinations included testing for serum levels of triglycerides, total cholesterol, aspartate transaminase, alanine transaminase, and uric acid. To avoid the potential problems of low awareness of diabetes and hypertension by self-reported history, we reconfirmed the diagnosis in the NHIRD with well-established information. We defined type 2 diabetes if the individual had had two or more outpatient visits or at least one hospital admission with a diagnostic code of diabetes (ICD-9-CM code 250). This definition of diabetes was validated by a study sampling 9,000 patients with a diagnosis of diabetes in the Taiwan National Health Insurance claims data, and the sensitivity and positive predictive value were high (94.8% and 74.6%, respectively). (22) The diagnosis of hypertension followed similar criteria, which included two or more outpatient visits or at least one hospitalization with a diagnosis of hypertension (ICD-9-CM, 401-405). The estimated GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation, and a low GFR was defined as an estimated GFR of <60 mL/min/1.73 m 2 . Proteinuria was defined as the presence of urinary protein at least grade 1 by the urine dipstick test.
STATISTICAL ANALYSIS
Categorical variables of participants with or without chronic HCV infection were expressed as numbers and percentages and compared using the chi-squared test. Continuous variables were expressed as means 6 standard deviation and compared using an unpaired t test. Person-years of each participant were calculated from the date of entry to the date of ESRD, death, or December 31, 2008, the final date of linked data availability. The incidence rate of ESRD was calculated by dividing the number of ESRD events by person-years of follow-up. The cumulative incidence of ESRD for chronically HCV-infected and nonchronically HCVinfected cases was estimated using the Kaplan-Meier method, and the statistical significance of the difference was compared using the log-rank test. Cox proportional hazard models were used to estimate multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of ESRD for HCV viral load and genotypes. The proportionality assumption of Cox models was checked and not violated. The interaction of HCV infection, diabetes, and hypertension was assessed. The statistical significance of the doseresponse relationship between serum HCV RNA levels, HCV genotypes, and the incidence of ESRD was assessed using the Cochran-Armitage test for trend. Statistical significance was determined by a two-tailed test (P < 0.05). Statistical analyses were mainly performed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC).
Besides the traditional Cox proportional hazard model, we aimed to further identify the predictors of the cumulative incidence of ESRD through a competing risk analysis, which considers two competing events: the development of ESRD and death prior to ESRD. Competing risk analyses were performed using the Cox proportional hazards regression for adjusted cause-specific HRs, and the Fine and Gray method was further used to incorporate rates of competing risks in the cumulative incidence function and subhazard ratios. (23) Statistical analyses for competing risk were performed using STATA software (version 12; StataCorp, College Station, TX), and the Fine and Gray model was implemented in the Stata statistical software using the "stcrreg" module.
Results
Baseline characteristics of the 19,984 study participants according to chronic HCV infection status are shown in Table 1 . There were 19,393 nonchronically HCV-infected subjects and 591 chronically HCVinfected subjects. The mean age of participants was 47.3 years. Participants who were chronically HCVinfected tended to be older, were more likely to be male, had lower educational levels, and were more likely to have diabetes and hypertension. Patients with chronic HCV infection also had lower GFR values, lower levels of cholesterol and triglycerides, and higher levels of alanine aminotransferase, uric acid, and urinary protein than participants without chronic HCV infection.
The median number of follow-up years was 16.8. A total of 204 ESRD events occurred during the 319,474 person-years. The incidence rate of ESRD was 63.9 per 100,000 person-years (60.2 per 100,000 personyears for nonchronically HCV-infected participants and 194.3 per 100,000 person-years for chronically HCV-infected participants). The incidence rates of ESRD and crude HR by baseline covariates are listed in Table 2 . The cumulative incidence of ESRD was 1.1% for nonchronically HCV-infected subjects and 3.4% for chronically HCV-infected subjects (logrank P < 0.001). Comparing participants with and without chronic HCV infection, the univariate and multivariable-adjusted HRs (95% CI) were 3.31 (2.02-5.45) and 2.33 (1.40-3.89), respectively.
The cumulative risk of developing ESRD was 3.2% for those with low HCV RNA levels and 3.7% for those with high HCV RNA levels (Fig. 2) . In model 1, the multivariable-adjusted HRs (95% CI) of those with low and high HCV RNA levels were 2.11 (1.16-3.86) and 3.06 (1.23-7.58), respectively, compared with those nonchronically-HCV-infected participants (P trend < 0.001) ( Table 3) . In model 2, the multivariable-adjusted HRs (95% CI) for participants with genotype 1 and genotype 2 compared with those who were not chronically HCV-infected were 3.60 (1.83-7.07) and 1.38 (0.60-3.18), respectively.
A total of 2,416 death events occurred during the follow-up period. After the competing risk of pre-ESRD death is taken into account, predictors of increased cumulative incidence of ESRD were old age; male gender; low educational level; diabetes; hypertension; CKD; and elevated triglycerides, cholesterol, uric acid, and urinary protein levels (see Supporting Table  S1 ). Comparing participants with and without chronic HCV infection, the multivariable-adjusted HR (95% CI) was 2.33 (1.39-3.89) in the cause-specific hazard method, and the subhazard ratio was 2.20 (1.24-3.90) in the Fine and Gray method. The multivariableadjusted HRs and subhazard ratios (95% CI) of those with low or high HCV RNA levels are listed in Table  4 . Cumulative incidence of ESRD increased with increasing HCV RNA levels (see Supporting Fig. S1 ), and the relationship between genotype 1 versus 2 did not change. 
Discussion
Our study demonstrated that chronic HCV infection is an independent risk factor for the development of ESRD. During more than 15 years of follow-up, chronic HCV infection resulted in a 2.2-fold increased risk of ESRD after taking pre-ESRD death as a competing risk. Compared with participants who were not chronically HCV-infected, participants with low and those with high HCV RNA levels had a 2.1-fold and Limited studies have examined the association between HCV infection and the risk of ESRD. In a diabetes study, Crook et al. found that patients with diabetes with HCV had worse renal survival and that the effects of HCV were independent of the development of ESRD after adjusting for potential confounders with an odds ratio of 3.49 (95% CI 1.27-9.57). (24) The first large cohort study was conducted in 2007, in which Tsui et al. retrospectively followed 474,369 US veterans aged 18-70 years and found that HCV seropositivity was associated with a greater than 2-fold risk of developing ESRD (adjusted HR, 2.80, 95% CI 2.43-3.23). (25) However, the study was restricted to veterans, and the follow-up time (median 3.6 years) was not long enough to observe the natural course of kidney disease progression. The current study is unique in that it used a community-based cohort in an endemic area. The results are generalizable. Furthermore, the study followed HCV infection and renal outcomes for more than 15 years, much longer than previous studies, in which the follow-up periods were less than 4 years. (12, 14, 15) The most encouraging feature of the current study is that we used serum HCV RNA levels as well as anti-HCV serostatus to define HCV infection. Most studies, including that of Tsui et al., (25) only had anti-HCV serotesting data, lacking evidence of whether the infection in the HCV-infected patients was active or not. A retrospective hospital-based study revealed that the number of patients with viral loads above the cutoff value of 600,000 was significantly higher in the group with CKD. (26) In addition, two HIV studies have demonstrated that in HIV-infected patients HCV viremia is associated with a higher incidence of CKD than in HCV-seronegative individuals. (27, 28) However, one study found that both HCV viremic and HCV aviremic HIV-infected individuals were at increased risk for moderate and advanced CKD, and another study showed that HCV aviremic patients had a similar incidence rate of CKD compared with anti-HCVnegative patients. The role of HCV aviremia in CKD remains a subject of debate. Our study demonstrates that the HCV RNA level increased the risk of ESRD in a dose-dependent manner among the general population. Patients with undetectable HCV RNA had a similar HR of developing ESRD compared to anti-HCV-seronegative patients, suggesting that viral load does play a role in the association between HCV infection and risk of developing ESRD.
HCV genotype has significant clinical importance in relation to the clinical manifestations of the disease and treatment response. In our group, Lee et al. explored the predictive value of HCV genotype for the development of hepatocellular carcinoma and demonstrated that HCV genotype 1 was an independent predictor of hepatocellular carcinoma. (20) In the current study, patients with HCV genotype 1 had a higher HR of developing ESRD than non-HCV-infected patients. This result was consistent across each stratum in subgroup analysis (data not shown). High prevalence of HCV genotype 1 was found among previous observational studies in hemodialysis units among South American, Asian, and European countries. (29) (30) (31) The mechanisms between HCV genotype and risk of ESRD need to be further investigated in the future.
Chronically HCV-infected patients have an increased risk of ESRD and death. (32) These two outcomes have competing effects that potentially interfere with risk samplings in the survival analysis. Thus, competing risk analysis should be performed on the HCV-ESRD association taking pre-ESRD death into consideration. In the current analysis, chronic HCV infection remained associated with a nearly 2-fold risk of developing ESRD after competing risk assessment, either in the cause-specific hazard model or in the Fine and Gray model. The dose-response effect of the HCV RNA level on the risk of incidence of ESRD was even robust and indicated that the HCV viral load is highly predictive of ESRD risk under competing risk consideration.
Recently, new direct-acting antiviral drugs that target key components of viral replication have been developed, which allow for more efficient and shortened treatments for HCV than the traditional interferon-based treatment. (33) If so, the use of directacting antiviral agents for HCV-infected patients is believed to effectively reduce the morbidity and mortality of liver-related disease. Our study provided strong evidence that the HCV viral load is predictive of ESRD in a dose-dependent manner; thus, viral eradication therapy might tremendously reduce the incidence of renal disease as well as liver disease. Although the new direct-acting antiviral agents are costly, the potential hepatic and extrahepatic benefits are valuable.
Our study has several limitations. First, our cohort was built in 1991-1992, and the first outcomes that could be traced by linking to the catastrophic illness registration were from 1995. Thus, some incident cases may be missing. The number was speculated to be low because we excluded participants with stage 5 CKD at first, and the remaining population could hardly develop ESRD within a short period; and if any did, it is unlikely that it was caused primarily by HCV. We also did a subanalysis to exclude individuals with estimated GFR <60 mL/min/1.73 m 2 at baseline; the deleterious effect of HCV RNA remained robust. Second, the number of cases was small: there were only 17 ESRD cases among the HCV-infected participants; thus, the impact of finer subdivision of HCV viral load and genotypes on ESRD could not be evaluated adequately. Third, we did not consider new HCV infection from enrollment to the date that the National Health Insurance database could be accessed. The misclassification was nondifferential, and the true magnitude of association may be underestimated. Fourth, anti-HCV serostatus HCV RNA levels, genotypes, and covariates were measured only at baseline. Though we did not repeat the HCV measurements during follow-up, we did check some of the participants with adequate serum samples at last follow-up. There was a significant correlation between HCV RNA levels at study entry and last follow-up (r 5 0.76, P < 0.001). Finally, we did not consider the effect of antiviral therapy in this cohort. In Taiwan, patients with chronic hepatitis C rarely received antiviral treatment until 2004, when patients fulfilling certain criteria could be reimbursed for treatment through the National Health Insurance. None of the participants underwent interferonbased therapy after confirmation from linking to the NHIRD. Hence, our study provided an excellent opportunity to examine serologic markers and kidney disease during the natural course of HCV infection.
In conclusion, this study is a reminder that the risk of ESRD among patients with chronic HCV infection may be underrecognized, especially among those with elevated serum levels of HCV RNA (>167,000 IU/ mL) and HCV genotype 1. All patients with chronic HCV infection should undergo a thorough renal survey at diagnosis and receive regular follow-up.
